The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials

Clin Ther. 2022 Aug 25:S0149-2918(22)00282-X. doi: 10.1016/j.clinthera.2022.08.003. Online ahead of print.ABSTRACTPURPOSE: We aimed to investigate the impact of anastrozole administration on the traditional components of the lipid profile (ie, total cholesterol [TC], LDL-C, HDL-C, and triglycerides [TGs]) by means of a systematic review and meta-analysis of randomized controlled trials.METHODS: We searched the PubMed/Medline, Scopus, Embase, and Web of Science databases for relevant randomized controlled trials published in the English language until January 18, 2022. The weighted mean difference (WMD) and 95% CIs were calculated using a random-effects model (DerSimonian and Laird methods).FINDINGS: Anastrozole administration significantly lowered TC concentrations when the treatment duration was ≤3 months (WMD = -2.73 mg/dL; 95% CI, -5.09 to -0.38 mg/dL; P = 0.02) and when the baseline TC concentration was ≥200 mg/dL (WMD = -3.64 mg/dL; 95% CI, -6.30 to -0.98 mg/dL; P = 0.007). HDL-C levels decreased after anastrozole administration when the treatment duration was >3 months (WMD = -1.67 mg/dL; 95% CI, -3.24 to -0.10 mg/dL; P = 0.03). Anastrozole administration had no impact on TG or LDL-C values.IMPLICATIONS: Anastrozole administration in humans can decrease TC and HDL-C levels but has no effect on LDL-C or TG concentrations.PMID:36031476 | DOI:10.1016/j.clinthera.2022.08.003
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research